Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05146219
Other study ID # TYKM1601201
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date April 2, 2022
Est. completion date December 2024

Study information

Verified date January 2024
Source TYK Medicines, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of TY-9591 tablets in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with brain or leptomeningeal metastases.


Description:

This is an open label, multi-center phase II study to evaluate the efficacy and safety in EGFR mutated NSCLC patients with brain or leptomeningeal metastases. The patients will be assigned to the appropriate treatment cohorts based on the criteria.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date December 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients diagnosed with non-small cell lung cancer (NSCLC) by histology or cytology, and with brain and leptomeningeal metastases. For LM patients, the diagnosis of leptomeningeal metastasis requires detection of cancer cell or EGFR mutation in the CSF. 2. Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites). A positive T790M mutation is required for patients who have progressed following prior 1/2 generation EGFR-TKI therapy. 3. Stable brain/leptomeningeal metastases that do not require immediate or planned local treatment for it during the study period. 4. Presence of intracranial and extracranial measurable lesions without local treatment at the same time. 5. The ECOG score is 0-2 (including 0 and 2), and there is no deterioration 2 weeks before the study, and the expected survival is not less than 3 months. 6. Adequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: 1. Absolute neutrophil count =1.5×109/L and white blood cell count =3×109/L; 2. Platelet count =100×109/L; 3. Hemoglobin =90g/L; 4. Serum creatinine =1.5× upper normal limit (ULN) and creatinine clearance =50 mL/min (calculated according to the Cockcroft and Gault formula); 5. AST and ALT=2.5×ULN if no confirmed liver metastasis; AST, ALT=5×ULN if confirmed liver metastasis; 6. Total bilirubin =1.5×ULN in the absence of proven liver metastasis; total bilirubin =3×ULN in patients with proven liver metastasis or Gilbert syndrome (hyperindirect bilirubinemia); 7. International standardized ratio (INR) =1.5, and activated partial prothrombin time (APTT) =1.5×ULN. 7. Male patients and female patients of reproductive age should take adequate contraceptive measures from signing informed consent to 3 months after the last study drug treatment; Women of childbearing age have negative pregnancy test results within 7 days of the first dose. 8. Patients having recovered from all grade = 1 toxicities related to previous anticancer therapies (CTCAE v 5.0) except for alopecia, platinum-therapy-related neuropathy (where =2 is allowed) before first dose of study treatment. 9. Patients can understand and voluntarily sign the informed consent form. 10. Patient able to comply with study requirements. Exclusion Criteria: 1. Any of the following treatment: 1. Previous treatment with 3rd generation EGFR inhibitor (Osimertinib, Almonertinib, Furmonertinib, etc.); 2. The time from the treatment of reversible EGFR-TKI (e.g., Gefitinib, Erlotinib, Icotinib) to the first administration of the drug in this study did not exceed 8 days or 5 half-lives (whichever is longer); the time from the treatment of irreversible EGFR-tkis (e.g., Afatinib, Dacomitinib, Neratinib, etc.) do not exceed 14 days or 5 half-lives (whichever is longer); 3. Previous treatment with Systematic antitumor therapy, including standard chemotherapy, biotherapy and immunodrug therapy within 28 days before the first dose of the study drug, and traditional Chinese medicine antitumor therapy within 7 days before the first dose of the study drug. 4. Receiving radiation to more than 30% of the bone marrow or with a wide field of radiation that had to be completed within 28 days of the first dose of study treatment; Radiotherapy with a limited field of radiation within 7 days of the first dose of study treatment or palliative radiation therapy for bone metastasis; 5. Previous treatment with whole brain radiotherapy (WBRT). Patients who have previously received stereotactic radiotherapy (SRT) or other CNS local treatments (such as intrathecal chemotherapy) can be enrolled if the time from the completion of treatment to the initial study medication is more than 2 weeks; 6. Uncontrollable pleural and abdominal effusion. For patients with pleural effusion, pleural effusion should be stabilized for 2 weeks prior to initial medication (diuretics, pleural effusion or pleural infusion are not allowed during this period); 7. Major surgery within 4 weeks of the first dose of study treatment; 8. Patients currently receiving (or at least within 14 days prior to receiving the first dose )medications or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 isoenzyme (CYP)3A4. 9. Patients who are receiving and need to continue receiving medications during the study that are known to prolong the QTc interval or may cause tachycardia; 10. Participants in other clinical trials (other than non-interventional clinical trials) within 28 days prior to the first administration of the investigational drug. 2. Patients with leptomeningeal metastases (LM) who cannot be examined with enhanced MRI. Presence of leptomeningeal metastases only. 3. Patients with CNS complications requiring emergency neurosurgical treatment (e.g. surgery, etc.). Patients with CNS symptoms should be controlled by glucocorticoids with an equivalent dose of more than 5mg dexamethasone 5 days prior to initial administration. 4. Patients have spinal cord compression caused by tumor. 5. Clinically severe gastrointestinal dysfunction may affect the ingestion, transport or absorption of the study drugs. 6. Cardiac function and disease are consistent with the following: 1. Corrected QT interval(QTc)> 470 milliseconds from 3 electrocardiograms (ECGs); 2. Any clinically important abnormalities in rhythm; 3. Any factors that increase the risk of QTc prolongation; 4. Left ventricular ejection fraction (LVEF) <50%. 7. Active human immunodeficiency virus (HIV), syphilis, hepatitis c virus (HCV) or hepatitis b virus (HBV) infection, with the exception of asymptomatic chronic hepatitis b or hepatitis c carriers. 8. Previous history of interstitial lung disease(ILD)#drug-induced ILD or radiation pneumonitis require steroid treatment, or any evidence of clinically active ILD diseases. 9. Previous allogeneic bone marrow transplant. 10. Pregnant or lactating women. 11. Any other disease or medical condition that is unstable or may affect the safety or study compliance. 12. Hypersensitivity to TY-9591 or similar compounds or excipients.

Study Design


Intervention

Drug:
TY-9591 Tablets
TY-9591 Tablets 160mg/d

Locations

Country Name City State
China National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
TYK Medicines, Inc

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intracranial Overall Response Rate (iORR) iORR is defined as the proportion of patients with a best intracranial response of complete response (CR) or partial response (PR) during the study treatment 13 months.
Primary Extracranial Overall Response Rate (eORR) eORR is defined as the proportion of patients with a best extracranial response of complete response (CR) or partial response (PR) during the study treatment 13 months.
Secondary Objective Response Rate (ORR) ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) during the study treatment 13 months.
Secondary Disease Control Rate (DCR) DCR is defined as the proportion of patients with a best overall response of complete response (CR) , partial response (PR) or Stable disease (SD) =6 weeks during the study treatment 13 months.
Secondary Duration of Response (DoR) DoR is defined as the time from the date of first documented response (PR or CR) until the date of first documented disease progression or death due to any cause during the study treatment 13 months.
Secondary Median Progression Free Survival (PFS) PFS is defined as time from date of first dose of study treatment until the date of first documented disease progression or death due to any cause 13 months.
Secondary Intracranial Median Progression Free Survival (iPFS) iPFS is defined as time from date of first dose of study treatment until the date of first documented intracranial disease progression or death due to any cause 13 months.
Secondary Overall Survival (OS) OS is defined as the time from the date of first dose of study treatment until death from any cause From the date of first dose until the date of death from any cause or loss to follow-up, whichever comes first, assessed up to 100 months
See also
  Status Clinical Trial Phase
Recruiting NCT05821933 - RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC Phase 1/Phase 2
Active, not recruiting NCT03269162 - Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection Phase 3
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT06315686 - The Dynamic Monitoring of Cerebrospinal Fluid ctDNA Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Recruiting NCT05466149 - Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT03609918 - Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Recruiting NCT06043817 - First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT05078931 - A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients Phase 2
Not yet recruiting NCT05547737 - Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Withdrawn NCT05959473 - EGFR_IUO 3.20 Clinical Study Protocol N/A
Not yet recruiting NCT05005468 - A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. Phase 2
Recruiting NCT01690390 - Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease Phase 2
Completed NCT01852578 - Cabazitaxel in Relapsed and Metastatic NSCLC Phase 2
Active, not recruiting NCT01460472 - Immunotherapy With Racotumomab in Advanced Lung Cancer Phase 3
Completed NCT00866970 - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia Phase 2
Completed NCT00702975 - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy Phase 2